| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.006 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.087 | 0.006 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.096 | 0.006 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.007 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.007 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.008 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.079 | 0.01 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |